Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 14:6:239.
doi: 10.3389/fonc.2016.00239. eCollection 2016.

Recent Advances in Immunotherapy in Metastatic NSCLC

Pranshu Bansal  1 , Diaa Osman  1 , Gregory N Gan  2 , George R Simon  3 , Yanis Boumber  4
Affiliations
Review

Recent Advances in Immunotherapy in Metastatic NSCLC

Pranshu Bansal et al. Front Oncol. .

Abstract

Non-small cell lung cancer (NSCLC) is one of most common malignancies and the leading cause of cancer deaths worldwide. Despite advances in targeted therapies, majority of NSCLC patients do not have targetable genomic alterations. Nevertheless, recent discovery that NSCLC is an immunogenic tumor type, and several breakthroughs in immunotherapies have led to rapid expansion of this new treatment modality in NSCLC with recent FDA approvals of programed death receptor-1 inhibitors, such as nivolumab and pembrolizumab. Here, we review promising immunotherapeutic approaches in metastatic NSCLC, including checkpoint inhibitors, agents with other mechanisms of action, and immunotherapy combinations with other drugs. With advent of immunotherapy, therapeutic options in metastatic NSCLC are rapidly expanding with the hope to further expand life expectancy in metastatic lung cancer.

Keywords: CTLA4; NSCLC; PD1; PDL1; cancer immunotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of action of clinically used immunotherapeutic agents.
See this image and copyright information in PMC

References

    1. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1(5023):841–7.10.1136/bmj.1.5023.841 - DOI - PMC - PubMed
    1. Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, et al. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol (2012) 137(6):978–85.10.1309/AJCP9Q6OVLVSHTMY - DOI - PubMed
    1. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 64(8):2865–73.10.1158/0008-5472.CAN-03-3066 - DOI - PubMed
    1. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 188(12):2205–13.10.1084/jem.188.12.2205 - DOI - PMC - PubMed
    1. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity (2007) 27(4):670–84.10.1016/j.immuni.2007.09.006 - DOI - PubMed